Environmental

Publicly available filings provide limited disclosure on emissions, energy use, and waste, leaving GNPX broadly in line with small-cap biotech peers that also report sparse environmental metrics.

The company’s asset-light research model likely reduces direct operational footprint versus manufacturing-heavy peers, but this advantage is modest because peer disclosures are similarly limited.

No material environmental controversies are evident in the provided information, which supports positioning near peers rather than above them on environmental risk management.

Absent detailed climate or resource-use reporting, GNPX cannot demonstrate stronger environmental governance than better-disclosing peers, constraining its relative ESG score.

Social

GNPX’s research-focused business model generally concentrates social exposure in clinical development and patient safety, a profile broadly comparable to other early-stage biotech peers.

The provided metrics show no evidence of large-scale workforce or manufacturing intensity, which can limit labor and community risk versus more operationally complex peers.

However, limited public evidence on trial diversity, patient access, and product stewardship makes it difficult to show stronger social practices than peers with more detailed disclosures.

Overall social positioning appears average because the company’s principal social risks are typical for the sector and not clearly mitigated better than peer companies.

Governance

The zero reported stock-based compensation to revenue and zero debt-to-equity ratio suggest a simple capital structure, but they do not by themselves indicate stronger governance than peers.

For a micro-cap biotech, limited operating scale often coincides with concentrated oversight and thinner disclosure, which can leave governance quality below more mature peers.

The absence of meaningful leverage reduces creditor-related governance pressure, yet it also reflects a development-stage profile that typically offers fewer governance safeguards than established peers.

Overall governance remains only moderate because disclosure depth and board-level evidence are insufficient to demonstrate a clear advantage over comparable biotech companies.

Overall Score

GNPX appears broadly average versus small-cap biotech peers, with limited disclosure and development-stage governance offsetting a relatively light operational ESG footprint.

Score Driver: Limited Public ESG Disclosure Versus Peers